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ABSTRACT 
The present study deals with the development and evaluation of controlled porosity osmotic pump (CPOP) tablets of Zidovudine–
Lamivudine. Wet granulation method was used for the development of core tablets. Core tablets were incorporated with HPMCE5 
LV polymer, different concentrations of fructose as osmogen and additives. The CPOP tablets were coated with cellulose acetate as a 
wall forming material, polyethylene glycol as flux regulating agent, and sorbitol acts as pore forming material in SPM. The 
formulated tablets were evaluated for FTIR, DSC, pre-compression parameters, post compression parameters, in vitro drug release 
study and scanning electron microscopy study. The optimized formulation had no significant effect on the pH and agitation intensity, 
but depends on the osmotic pressure of dissolution media indicated that mechanism of drug release. SEM images revealed that no 
pores were found before dissolution and after dissolution had shown the porous nature of the membrane. Short term stability study at 
40±2ºC /75±5% RH for the months on the CF4 formulation indicated that there was no significant change weight variation, % 
friability, drug content and in vitro drug release. 
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INRODUCTION 
Controlled release dosage forms is the part of modified 
drug release dosage form which covers a wide range of 
prolonged 
1
 action which provide continuous release of 
their active ingredients at predetermined rate and 
predetermined time. Out of various controlled drug 
delivery systems osmotic controlled drug delivery 
system (OCDDS) utilizes principle of osmotic pressure 
2
 
to control the delivery of active ingredients. The drug 
released from OCDDS is independent of p
H
, 
hydrodynamic condition of the body and agitation 
intensity.  
The present study is to develop controlled porosity 
osmotic pump tablets. CPOP tablets were developed 
where the delivery orifices were formed by the 
incorporation of a leachable component 
3
 in SPM. The 
core is coated with cellulose acetate containing in situ 
micro pore former sorbitol. Once CPOP tablets come in 
contact with the aqueous environment of biological 
system the water soluble component dissolves and an 
osmotic pumping system is created in the core. Hence 
water diffuses into the core though the micro porous 
4
 
membrane setting up an osmotic gradient and thereby 
controlling the release of drug.  
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Globally AIDS is considered a dangerous disease which 
is caused by infection with human immune deficiency 
virus. The final stage of AIDS where the CD4+ count 
declines to 200cells/µL. Out of various treatments now 
antiretroviral 
5
 therapies plays a vital role for controlling 
the progression of AIDS. Combination therapy is used to 
be the advanced care of HIV infected patients. The 
current formulation containing 300 mg Zidovudine and 
150 mg of Lamivudine has been formulated as an oral 
therapy (tablet) for the treatment of HIV-1 infection in 
adults. The development of this fixed dose combination 
6
 
aims to reduce the number of daily tablets, enhance the 
compliance therapy and thereby minimizing the risk of 
emergence of resistance. 
MATERIALS AND METHODS 
Materials 
Zidovudine and Lamivudine were obtained from Hetero 
Drugs Pvt. Ltd. India. Fructose and mannitol were 
purchased from Qualigens Fine Chemicals, India. 
Cellulose acetate (CA) was obtained from Eastman 
Chemical Inc, Kingsport, TN. Sorbitol, HPMC E5 LV, 
magnesium stearate, talc and polyethylene glycol (PEG) 
400, 600, 4000, 6000 were purchased from S.D. Fine 
Chemicals Ltd, Mumbai, India. Microcrystaline 
cellulose (MCC) and starch are purchased from Signet 
Pharma, Mumbai, India. All other solvents and reagents 
used were of analytical grade. 
Compatibility studies 
Fourier Transform Infrared Spectroscopy (FTIR) 
In this method individual samples as well as the mixture 
7
 of drug and excipients were ground mixed thoroughly 
with potassium bromide (1:100) for 3-5 minutes in a 
mortar and compressed into disc by applying pressure of 
10 kg/cm to form a transparent pellet in hydraulic press. 
The pellet was kept in the sample holder and scanned 
from 4000 to 400 cm
-1 
in FTIR spectrophotometer 
(Bruker, Germany). 
Differential Scanning Calorimetry (DSC) 
Physical mixtures of drug and individual excipients in 
the ratio of 1:1 were taken and examined in DSC 
(Shimadzu DSC-50, Japan).Individual samples as well 
as physical mixture of drug and excipients 
8
 were 
weighed to about 5mg in DSC pan. The sample pan was 
crimped for effective heat conduction and scanned in the 
temperature range of 50-300
0
C. Heating rate of 20
0
C 
min
-1
was used and the thermogram obtained was 
reviewed for evidence of any interactions.  
Methods 
Preparation of CPOP tablets 
Wet granulation technique was used to develop CPOP 
core tablets. Accurately weighed quantities of 
ingredients mentioned in Table 1 were sifted though 
sieve No. 30. Lubricant (magnesium stearate) and 
glidant (talc) were sifted though sieve No. 80.The 
ingredients were manually blended homogenously in a 
mortar by way of geometric dilution except lubricant 
and glidant. The mixture was moistened with aqueous 
solution and granulated though sieve No.30 and dried in 
a hot air oven at 60ºC for sufficient time (3-4 hrs). The 
dried granules were passed though sieve No.30 and 
blended with talc and magnesium stearate. The 
homogenous blend was then compressed into round 
tablets with standard concave punches using 10 station 
rotary compression machines (Mini press, Karnavati, 
India).
 
Table1: Composition of controlled porosity osmotic pump tablets of zidovudine-lamivudine combination 
Ingredients (mg)  CF1 CF2 CF3 CF4 
ZD 300 300 300 300 
LD 150 150 150 150 
MCC 150 120 90 60 
Starch 50 50 50 50 
HPMC E5LV 60 60 60 60 
Fructose 30 60 90 120 
Magnesium stearate 5 5 5 5 
Talc 5 5 5 5 
Total weight(mg) 750 750 750 750 
 
Coating of core tablets 
The coating solution was prepared taking required 
ingredients from table 2 and acetone was added quantity 
sufficient maintaining proper viscosity of solution. The 
coatings of tablets were performed by spray pan coating 
in a perforated pan (GAC-205, Gansons Ltd, Mumbai, 
India). Hot air is supplied to tablet bed by rotating lower 
speed 5-8 rpm initially. The coating of tablets was 
carried out with the rotation speed of 10-12 rpm. The 
spray rate and atomizing air pressure were 4-6 ml/min 
and 1.75 kg/cm
2 
respectively. Inlet and outlet air 
temperature were 50ºC and 40ºC respectively. Coated 
tablets were dried at 50ºC for 12 h. 
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Table 2: Coating composition for controlled porosity osmotic pump tablets 
Formulation code CA          
(g) 
PEG 400 
(g) 
PEG 600 
(g) 
PEG 4000 
(g) 
PEG 6000 
(g) 
Sorbitol 
(g) 
Acetone 
(mL) 
CF1 6 2 0 0 0 0 300 
CF2 6 0 2 0 0 0.6 300 
CF3 6 0 0 2 0 1.2 300 
CF4 6 0 0 0 2 1.8 300 
 
Evaluation of granules 
The prepared granules were evaluated for pre 
compression parameters such as angle of repose, bulk 
density, tapped density and compressibility index (Carr’s 
index). Fixed funnel method was used to determine 
angle of repose. The bulk density and tapped density 
were determined by bulk density apparatus (Sisco, 
India). 
The Carr’s index can be calculated by the following 
formula. 
%Carr’s index 
     
  
 100                                       (1) 
Where et is the tapped density of granules and eb is bulk 
density of granules.  
Hausner’s ratio can be calculated by the taking the ratio 
of tapped density to the ratio of bulk density 
9
.  
Evaluation of tablets 
10
 
Thickness 
The thickness of individual tablets is measured by using 
vernier caliper (Absolute digimatic, Mitutoyo Corp. 
Japan).The limit of the thickness deviation of each tablet 
is  5%. 
Measurement of coat thickness 
Film was isolated from the tablets after 18hs of 
dissolution and dried at 40
0
C for 1h.Thickness was 
measured by using electronic digital calipers (Absolute 
digimatic, Mitutoyo Corp. Japan)  
Hardness 
The hardness of tablets can be determined by using 
Monsanto hardness tester (Sisco, India).  
Friability test 
Friability test of tablets was performed in a Roche 
friabilator (SISCO, India).Twenty tablets of known 
weight (W1) were de-dusted in plastic chamber of 
friabilator for a fixed time of 25 rpm for 4 minutes and 
weighed again of weight (W2).The percentage of 
friability was calculated using the following equation. 
%Friability=        
   
   
                               (2)                                                                                                                
Where, W1 and W2 are the weight of the tablets before 
and after the test respectively.  
Weight variation test 
 
The weight variation test is performed by weighing 20 
tablets individually calculating the average weight and 
comparing the individual tablet weights to the average. 
The percentage weight deviation was calculated and then 
compared with USP specifications. 
 
Uniformity of drug content test  
Powder is made after triturating 10 CPOP tablets from 
each batch with mortar and pestle. The powder weight 
equivalent to one tablet was dissolved in a 100ml 
volumetric flask filled with 0.1N HCl using magnetic 
stirrer for 24 h. Solution was filtered though Whatman 
filter paper No.1 diluted suitably and analyzed spectro 
photometrically 
Diameter of tablet 
The diameter of individual tablets is measured by using 
vernier caliper (Absolute digimatic, Mitutoyo Corp. 
Japan). 
In vitro dissolution studies  
The in vitro dissolution 
11
 studies were carried out using 
USP apparatus type II (Lab India 8000) at 75 rpm. For 
the first 2 h the dissolution medium was 0.1N HCl (pH 
1.2) and phosphate buffer pH 6.8 from 3-8 h (900 ml), 
maintained at 37±0.5
0
C. At each time point 5 ml of 
sample was withdrawn and it was replaced with 5 ml of 
fresh medium. The drug release at different time interval 
was measured by UV-visible spectrophotometer (UV-
1800, Shimadzu, Japan). 
In vitro drug release kinetic studies 
12, 13
 
In order to investigate the mode of release from tablets, 
the release data of formulation was analyzed zero order 
kinetics, first order kinetics, Higuchi model and 
Korsmeyer-Peppas and Hixson-Crowell equations.  
Effect of osmogen concentration  
Keeping all the parameters for tablet constant different 
osmogen 
14
 concentrations were used to prepare tablets. 
The drug release was compared with the different 
osmogen concentration of formulated batches by using 
USP-II dissolution apparatus. 
Effect of pore former concentration  
SPM for various batches were prepared by taking 
different concentrations of pore former 
15
. The effect of 
pore former on in vitro release profile  is compared as 
well as number of formation of micropores were 
observed. 
Effect of membrane thickness  
Tablets with varying coating thicknesses were developed 
to demonstrate the effect of coating thickness on drug 
release. The drug release rate was measured using 0.1N 
HCl and phosphate buffer pH6.8 as a dissolution 
medium.  
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Effect of flux regulating agents 
To assess the effect of flux regulating agents on drug 
release, formulations were developed with different flux 
regulating agents keeping all other parameters of tablet 
constant. The drug release was compared with the 
different flux regulating agents of formulated batches by 
using USP-II dissolution apparatus. 
Effect of osmotic pressure  
The effect of osmotic pressure 
16
 was demonstrated by 
adding different amount of mannitol of an osmotic agent 
to produce 30 atm, 60 atm and 90 atm respectively in 
dissolution media 0.1N HCl for 2 h and phosphate buffer 
pH 6.8 for remaining hours. The drug release rate was 
carried out in USP type II (Paddle) apparatus at 75 rpm 
maintained at 37±0.5
0
C and compared for various 
dosage forms. 
Effect of pH  
The effect of pH 
17
 for developed formulations were 
observed by performing the release studies of optimized 
formulation in different media 0.1 N HCl (pH 1.2), 
phosphate buffer pH 6.8  and phosphate buffer in pH 7.4 
USP type II dissolution apparatus at 75 rpm. The 
temperature was maintained at 37±0.5°C. The release 
was studied at predetermined time intervals. 
Effect of agitation intensity  
The effect of agitation 
18
 intensity were observed by 
performing the release studies of optimized formulation 
in USP Type II (Paddle) dissolution apparatus 
containing 0.1NHCl for first 2 h and phosphate buffer 
pH 6.8 for remaining hours at different rotational speeds 
of 50,100 and 150 rpm with maintaining temperature at 
37±0.5°C.The samples were withdrawn at predetermined 
intervals and analyzed by UV spectrophotometer. 
Scanning Electron Microscopy (SEM)  
Coating membranes of formulation were collected 
before and after complete dissolution of core contents 
and examined for their porous morphology 
19
 as well as 
mechanism of drug release by scanning electron 
microscope (Leica, Bensheim, Switzerland). Scans were 
taken at an excitation voltage in SEM fitted with ion 
sputtering device.  
Accelerated stability studies  
The packed tablets in air tight container were placed in 
stability chambers (Thermo lab Scientific equipment 
Pvt. Ltd., Mumbai, India) maintained at 40±2
0
C/75±5% 
RH conditions for accelerated testing) for 3 months 
20
. 
Tablets were periodically removed and evaluated for 
physical characteristics, drug content, in‐vitro drug 
release etc.. 
RESULTS ANS DISCUSSION 
FTIR studies: 
FTIR spectra (Figure 1) of Zidovudine shows the 
characteristic absorption peaks for the carbonyl group at 
1638.76 cm
-1
, N=N
+
=N stretching (azido group) at 
2114.50 cm
-1
,C-O stretching at 1063.08 cm
-1
 and amine 
group stretching at 3317.86 cm
-1
. Figure 2 shows 
characteristic absorption peaks of Lamivudine for the C-
H stretching at 2843.83 cm
-1
, N-H bending at 1640.32 
cm
-1
,C-N stretching at 1010.71 cm
-1
,O-H in plane 
bending at 1054.55 cm
-1
 and amine group stretching at 
3326.6 cm
-1
.  
The major peaks of HPMCE5LV were found at 3880.71, 
3810.87, 3713.83, 3669.20, 3601.84, 3566.74, 3557.95, 
3473.68, 3222.79, 3117.03, 3066.96, 2982.59, 2887.86, 
2847.2, 2803.12, 2710.75, 2618.99, 2444.13, 
2335.14,2068.70, 1661.47, 1536.52, 1500.67, 1424.62, 
1071.87, 781.05 and 584.97 cm
-1
.The major peaks of 
fructose were found at 3450.75, 3120.47, 3047.75, 
2722.80, 2464.30, 2310.70, 2102.48, 1914.04, 1502.21, 
1391.71, 1102.14, 787.25, 677.36, and 599.13 cm
-1
. 
In the optimized formulation CF4 peak at 3672.66, 
1451.54, 1251.27 and782.94 cm
-1 
were due to presence 
of the polymer HPMCE5LV.In the formulation the 
peaks present due to fructose were 2986.84, 1230.38 and 
688.81 cm
-1
.Peaks at 3220.52 and 1065.68cm
-1
 were due 
to presence of the drug Zidovudine in the optimized 
formulation and peaks at 1650.23 and 3326.98 cm
-1
 were 
due to presence of the drug Lamivudine. So from the 
study it can be concluded that the major peaks of drug 
3220.52, 1065.68, 1650.23 and 3326.98 cm
-1
 remain 
stable and no interaction was found between the drug, 
polymer and osmogen. 
  
 
Figure 1: FTIR spectroscopy study of pure Zidovudine 
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Figure 2: FTIR spectroscopy study of pure Lamivudine 
 
Figure 3: FTIR spectroscopy study of CF4 
  
Figure 4: DSC study of Zidovudine 
 
 
Figure 5: DSC study of Lamivudine 
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DSC Study 
Figure 4 indicates that the endothermic peak of 
Zidovudine is at 114.5
0
C.The endothermic peak of 
Lamivudine is showing at 162.2
0 
C (Figure 5).The 
endothermic peak of CF4 formulation (Figure 6) is 
showing at117.6
0
C for Zidovudine and 171.2
0
C for 
Lamivudine. There were no significant changes in the 
endotherm peak between drug and formulation. 
 
 
Figure 6: DSC study of CF4 
 
Pre compression parameters: 
All the compressible excipients for various batches were 
evaluated for angle of repose, bulk density, tapped 
density, Carr’s index and Hausner’s ratio. All the values 
were within acceptable limits. It is given in Table 3. 
 
Post compression parameters 
Tablets were evaluated for different post compression 
parameters such as thickness, coat thickness, hardness, 
%friability, drug content and diameter. All evaluated 
values were in acceptable limits. It is mentioned in Table 
4.
Table 3: Pre compression parameters of powder blend 
Formulation 
code 
Angle of repose 
(degree)
a
± S.D 
Bulk density 
(g/ml)
a
± S.D 
Tapped density 
(g/ml)
a
± S.D 
Carr’s Index 
(%)
a
± S.D 
Hausner’s Ratioa± 
S.D 
 
CF1 27.39 0.12 0.494 0.08 0.536 0.14 7.83 0.08 1.08 0.14 
CF2 26.20 0.13 0.492 0.06 0.538 0.12 8.55 0.06 1.09 0.12 
CF3 25.08 0.13 0.488 0.12 0.524 0.11 6.87 0.08 1.07 0.11 
CF4 24.12 0.14 0.485 0.13 0.518 0.12 6.37 0.06 1.06 0.12 
All values are expressed as mean  S.D, a n = 3 
 
Table 4: Post compression parameters of CPOP tablets 
Formulation 
code 
Thickness 
(mm)
a
± 
S.D 
Coat 
thickness 
(µm)
a
± 
S.D 
Hardness 
(kg/cm
2
)
a
 
±S.D 
%Friability 
(%)
b 
± S.D 
%Weight 
variation 
(%)
b
 
%Drug 
content 
(%)
a
 
± S.D(ZD) 
%Drug 
content 
(%)
a
 
± S.D 
(LM) 
Diameter 
(mm)
a
± 
S.D 
CF1 4.02 0.12 251.3 3.1 6.9 0.12 0.15 0.04 1.59±0.22 99.16 0.83 99.02 0.83 10.11 0.04 
CF2 4.05 0.14 200.7 2.9 6.7 0.13 0.17 0.05 1.45±0.21 98.88 0.64 98.05 0.64 10.61 0.06 
CF3 4.03 0.12 150.6 3.3 7.3 0.12 0.18 0.06 1.28±0.13 99.44 0.52 99.11 0.52 10.15 0.04 
CF4 4.02 0.03 100.6 3.1 6.6 0.11 0.13 0.09 1.12±0.25 100.0 0.59 99.47 0.59 10.03 0.02 
N.B.-All values are expressed as mean  S.D, a n = 10, b n = 20 
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In vitro dissolution study  
The in vitro drug release characteristics were studied in 
900ml of 0.1N HCl (pH1.2) for a period of first 2 h and 
3 to 8 h in phosphate buffer pH 6.8 using USP type II 
dissolution apparatus (Paddle type). The cumulative 
percentage drug release of Zidovudine for CF1, CF2, 
CF3 and CF4 were 82.03 1.98, 84.41 1.83, 
89.37 1.21, and 94.14 1.22 respectively at the end of 8 
h. It is shown in figure 7. Similarly the cumulative 
percentage drug release of Lamivudine for CF1, CF2, 
CF3 and CF4 were 85.86 1.89, 89.96 1.93, 
92.34 1.92, and 96.89 1.02 respectively at the end of 8 
hrs. It is shown in figure 8. 
 
 
Figure 7: In vitro release profiles showing Zidovudine 
release from various fabricated formulations CF1-CF4 
(n=3) 
 
 
Figure 8: In vitro release profiles showing Lamivudine 
release from various fabricated formulations CF1-CF4 
(n=3) 
Kinetic model 
From the kinetic it is observed that all the formulations 
follow non-Fickian transport mechanism for Zidovudine 
as the n value is showing more than 0.45 in all 
formulations. It is shown in table 5.Similarly for 
Lamivudine the kinetic study was observed showing 
CF1 non-Fickian transport mechanism and CF2, CF3 
and CF4 follow Fickian diffusion mechanism for 
Lamivudine. It is shown in table 6. 
Table 5: Fitting of IVDR data for Zidovudine from combination in various mathematical models 
Models(Z) Zero order First order Higuchi Korsmeyer-Peppas Hixson-Crowell 
Batches R
2
 K0 R1
2
 K1 RH
2
 KH  RK
2
 Kkp n R
2
 Ks 
CF1 0.964 9.779 0.991 0.209 0.982 30.09 0.987 22.75 0.618 0.995 0.248 
CF2 0.948 10.04 0.992 0.232 0.987 31.22 0.984 25.46 0.585 0.992 0.266 
CF3 0.943 10.51 0.982 0.278 0.984 32.75 0.964 28.64 0.549 0.989 0.301 
CF4 0.912 10.66 0.972 0.347 0.994 33.94 0.983 35.31 0.475 0.987 0.345 
 
Table 6: Fitting of IVDR data for Lamivudine from combination in various mathematical models 
Models(L) Zero order First order Higuchi Korsmeyer-Peppas Hixson-Crowell 
Batches R
2
 K0 R1
2
 K1 RH
2
 KH  RK
2
 Kkp n R
2
 Ks 
CF1 0.909 9.953 0.986 0.246 0.989 31.64 0.975 31.18 0.502 0.975 0.275 
CF2 0.880 9.958 0.990 0.278 0.991 32.2 0.983 36.64 0.439 0.976 0.295 
CF3 0.861 10.33 0.984 0.327 0.986 33.69 0.983 39.17 0.434 0.967 0.330 
CF4 0.844 10.38 0.982 0.405 0.985 34.21 0.990 43.85 0.390 0.984 0.371 
 
Effect of osmogen concentration 
The concentrations of fructose varied 30, 60, 90, and 
120 mg/tab in CF1, CF2, CF3, and CF4 respectively. 
The cumulative drug release was in order 
CF4 CF3 CF2 CF1 for both Zidovudine and 
Lamivudine respectively. It was observed that osmogent 
enhances the drug release of drug and thus had a direct 
effect on drug release. The drug release profile was 
shown in figure 7 for Zidovudine and figure 8 for 
Lamivudine. 
Effect of pore former concentration 
Batches CF1 to CF4 the coating composition of pore 
forming agent of sorbitol were 0%, 10%, 20% ,and 30% 
w/w of CA of sorbitol respectively. The cumulative drug 
release was in order CF4 CF3 CF2 CF1 for both 
zidovudine and lamivudine respectively. It confirms that 
as the level of pore former increases the membrane 
becomes more porous after coming contact with 
aqueous environment resulting in faster drug release. 
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The drug release profile was shown in figure 7 for 
Zidovudine and figure 8 for Lamivudine. 
Effect of membrane thickness 
Release profiles of CPOP tablets from various batches 
varying the coating thickness were evaluated. The order 
of coating thickness for CF1 to CF4 is 
CF1 CF2 CF3 CF4.  It was clearly evident that drug 
release was inversely proportional to coating thickness 
of the semi permeable membrane. The drug release 
profile was shown in figure 7 for Zidovudine and figure 
8 for Lamivudine. 
Effect of flux regulating agents  
The concentrations of flux regulating agents (PEG400, 
PEG600, PEG4000, and PEG6000) were 33.3% w/w of 
CA in coating solution in CF1, CF2, CF3, and CF4 
respectively. The cumulative drug release was in order 
CF4 CF3 CF2 CF1 for both zidovudine and 
lamivudine respectively. It is observed that type of flux 
regulating agents have pronounced effect on drug 
release. Hence the type of flux regulating agents on drug 
release is written as PEG6000  
PEG4000 PEG600 PEG400. The drug release profile 
was shown in figure 7 for Zidovudine and figure 8 for 
Lamivudine. 
Effect of osmotic pressure on optimized formulation 
The results of release studies of optimized formulation 
in media of different osmotic pressure indicated that the 
drug release is highly dependent on the osmotic pressure 
of the release media. The release was inversely related 
to the osmotic pressure of release media. This finding 
confirms that the mechanism of drug release is by 
osmotic pressure. The drug release of Zidovudine for 
CF4 was found to be 90.32 1.71% for 30 atm, 
86.78 1.72% for 60 atm and 82.43 1.74% for 90 atm 
respectively. It is shown in figure 9.Similarly the drug 
release of Lamivudine for CF4 was found to be 
93.47 1.74% for 30 atm, 89.16 1.74% for 60 atm and 
84.28 1.70% for 90 atm respectively. It is shown in 
figure 10. 
Effect of pH  
The optimized formulation CF4 was subjected to in 
vitro drug release studies of Zidovudine and Lamivudine 
differently in buffers with different pH like pH 1.2, pH 
6.8 and pH 7.4. It is observed that there is no significant 
difference in the release profile for Lamivudine and 
Zidovudine from combination, demonstrating that the 
developed formulation shows pH independent release. 
Effect of agitation intensity  
The optimized formulation of CF4 batch was carried out 
in USP dissolution apparatus type-II at varying 
rotational speed (50,100 and 150rpm) for Zidovudine 
and Lamivudine from combination. It shows that the 
release of both the drugs from CPOP is independent of 
agitation intensity.  
 
Figure 9: In vitro release profiles showing Zidovudine 
release from best CF4 in different osmotic pressures 
  
 
 
Figure 10: In vitro release profiles showing Lamivudine 
release from best CF4 in different osmotic pressures 
Scanning Electron Microscopy (SEM)  
The coating membrane of the osmotic delivery system 
before and after dissolution was examined with the help 
of SEM. Before dissolution (Figure11a) no pores were 
found in the coating membrane. But after dissolution 
(Figure11b) comparatively more numbers of pores were 
found in the membrane might be due to leaching or 
removal of entrapped drug from the formulation. The 
porosity nature of the membrane was due to the 
presence of pore forming agent sorbitol in the 
formulation. 
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a) SEM before dissolution                                      b) SEM after dissolution 
Figure 11: a) SEM of membrane structure of optimized formulation before dissolution, b) SEM of membrane 
structure of optimized formulation after dissolution 
 
Stability studies 
From short term stability studies of optimized 
formulation CF4, it was confirmed that there was no 
significance changes in physical appearance and drug 
content. It is shown in table 7. 
 
Table 7: Comparative physicochemical characterization of CF4 at accelerated conditions 
S.N. Parameters Initial After 30 
days 
After 60 
days 
After 90 
days 
1. Physical appearance Pale white, circular, concave 
smooth surface without any 
cracks 
No change No change No change 
2. Thickness(mm)
a
 ± S.D 4.02 0.03 4.02 0.03 4.01 0.02 4.01 0.05 
3 Hardness(kg/cm
2
)
a
 ± S.D 6.6 0.11 6.6 0.11 6.5 0.14 6.5 0.12 
4. Friability(%)
a
 ± S.D 0.13 0.09 0.13 0.09 0.14 0.08 0.14 0.06 
5 Weight variation(mg)
b
 ± S.D 1.12±0.25 1.12±0.25 1.13±0.29 1.15±0.25 
6. Drug content(%)
a
 ± S.D(ZD) 100.0 0.59 100.0 0.59 99.2 0.52 99.17 0.56 
7. Drug content(%)
a
 ± S.D(LM) 99.47 0.59 99.47 0.59 99.11 0.25 99.08 0.32 
N.B.-All values are expressed as mean  S.D, a n = 10, b n = 20 
 
CONCLUSION 
The drug release from CPOP was in predetermined rate 
and predetermined time by incorporating controlled 
release polymer and osmogen. It was confirmed that 
increase in concentration of osmogen the drug release 
from the system was found to be increased.SEM study 
reveals that the mechanism of drug releases due to 
osmogen as well as pore former. Hence this can be used 
to develop newer formulations to avoid shortcomings of 
conventional dosage forms. 
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